Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and c‐ros oncogene 1 (ROS1) have been established as efficient cancer treatments.1, 2, 3, 4, 5 However, concomitant mutations in these driver genes, as well as in the KRAS and BRAF oncogenes, have been reported frequently in recent years.6, 7 Moreover, case series reports presented various treatment procedures and different results. The gene discussed is ALK; the disease is cancer.